Disease landscape
Lung cancer (NSCLC)
The GAP analysis for non-small cell lung cancer (NSCLC) revealed moderate limitations in access to both diagnosis and treatment. The scores obtained range from 41 points for Slovakia to 63-64 points for Poland and Hungary. The differences are mainly due to differences in the proportion of patients treated with PD-1/PD-L inhibitors. It is noteworthy that in all V4 countries, the reimbursement process has not kept pace with the very dynamic drug registration process. The reimbursement index describing the availability and limitations of public funding ranges from 24 to 35 points.
Cross-Country
General GAP for NSCLC
Compliance with guidelines
Of the 31 drugs recommended by the ESMO clinical practice guidelines, 52-56% are available in the V4 countries. In almost every case, however, this is reimbursement with limitations.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
pd-1/pd-l1
Drug access
Number of patientS treated (2023)
Drug access
POPULATION treated pd-1/pd-l1 (%)
Main issues
- The average time to reimbursement for NSCLC drugs in the V4 countries is more than 2.8 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 2.1 years.
- The proportion of patients in the target population treated with PD-1/PD-L1 inhibitor drugs in V4 countries varied widely between the V4 states in 2023: from 15% in Slovakia up to 65% in Poland.
- The population burden defined by DALYs (disability adjusted life-years) in lung cancer is significant in all V4 countries.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).